Zentalis at Stifel 2026 Healthcare Conference: dual path for azenosertib

On 11 November 2026, Zentalis Pharmaceuticals Inc. presented a two-pronged strategy for its WEE1 inhibitor, azenosertib, at the Stifel 2026 Healthcare Conference. The drug, currently in development for ovarian cancer, could reach the market either through accelerated approval based on DENALI Part 2 or full approval following the ASPENOVA Phase III trial.

DENALI Part 1B, which showed a 37% overall response rate and median overall survival of approximately 16 months, provided encouraging clinical data. The company's cash reserves of about $229 million would support operations through the first half of 2028. Zentalis aims to differentiate azenosertib from existing treatments like chemotherapy and antibody-drug conjugates by focusing on a specific biomarker, Cyclin E1 expression.

The drug is being tested in combination strategies for platinum-sensitive disease and future partnerships for global expansion. CEO Julie Eastland emphasized the potential of azenosertib as a first-in-class oral therapy for platinum-resistant ovarian cancer, which has limited treatment options. The data support azenosertib as a differentiated option even as new competitors enter the ovarian cancer market.